DK3833434T3 - Forbindelser, der er nyttige ved modulering af farnesoid-x-receptoren, samt fremgangsmåder til fremstilling og anvendelse heraf - Google Patents
Forbindelser, der er nyttige ved modulering af farnesoid-x-receptoren, samt fremgangsmåder til fremstilling og anvendelse heraf Download PDFInfo
- Publication number
- DK3833434T3 DK3833434T3 DK19759119.1T DK19759119T DK3833434T3 DK 3833434 T3 DK3833434 T3 DK 3833434T3 DK 19759119 T DK19759119 T DK 19759119T DK 3833434 T3 DK3833434 T3 DK 3833434T3
- Authority
- DK
- Denmark
- Prior art keywords
- farnesoid
- modulating
- receptor
- procedures
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862716015P | 2018-08-08 | 2018-08-08 | |
| PCT/US2019/045266 WO2020033382A1 (en) | 2018-08-08 | 2019-08-06 | Compounds useful in modulating the farnesoid x receptor and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3833434T3 true DK3833434T3 (da) | 2022-02-14 |
Family
ID=67766286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19759119.1T DK3833434T3 (da) | 2018-08-08 | 2019-08-06 | Forbindelser, der er nyttige ved modulering af farnesoid-x-receptoren, samt fremgangsmåder til fremstilling og anvendelse heraf |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11339153B2 (da) |
| EP (2) | EP3833434B1 (da) |
| JP (1) | JP7457020B2 (da) |
| KR (2) | KR20220087471A (da) |
| CN (1) | CN112638473B (da) |
| AU (1) | AU2019319750A1 (da) |
| BR (1) | BR112021002050A2 (da) |
| CA (1) | CA3106033A1 (da) |
| DK (1) | DK3833434T3 (da) |
| ES (1) | ES2907187T3 (da) |
| IL (1) | IL280520B2 (da) |
| MX (1) | MX2021001513A (da) |
| PH (1) | PH12021550214A1 (da) |
| PL (1) | PL3833434T3 (da) |
| SA (1) | SA521421189B1 (da) |
| WO (1) | WO2020033382A1 (da) |
| ZA (1) | ZA202101119B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US20230096663A1 (en) * | 2020-02-11 | 2023-03-30 | Inorbit Therapeutics Ab | Farnesoid x receptor modulating compounds and methods of using the same |
| EP4161925A4 (en) * | 2020-06-09 | 2024-09-04 | Viking Therapeutics Inc | COMPOSITIONS AND METHODS FOR TREATING LIVER DISORDERS |
| CN114656460A (zh) * | 2020-12-22 | 2022-06-24 | 江苏天士力帝益药业有限公司 | 一种新型吡嗪结构fxr激动剂、制备方法及应用 |
| WO2022179636A1 (zh) * | 2021-02-27 | 2022-09-01 | 轩竹生物科技股份有限公司 | Fxr受体激动剂的晶型 |
| CN115504972A (zh) * | 2021-06-22 | 2022-12-23 | 广东药科大学 | 异恶唑类衍生物、其制备方法及其作为药物的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2288084A1 (fr) * | 1974-10-17 | 1976-05-14 | Chevron Res | Nouveaux alpha-halogenacetanilides, leur preparation et leur application comme fongicides et herbicides |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| AR108711A1 (es) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| EP3504205B1 (en) * | 2016-08-23 | 2021-08-04 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic conditions and disorders |
| CN107973790A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
-
2019
- 2019-08-06 DK DK19759119.1T patent/DK3833434T3/da active
- 2019-08-06 PL PL19759119T patent/PL3833434T3/pl unknown
- 2019-08-06 BR BR112021002050-0A patent/BR112021002050A2/pt unknown
- 2019-08-06 ES ES19759119T patent/ES2907187T3/es active Active
- 2019-08-06 EP EP19759119.1A patent/EP3833434B1/en active Active
- 2019-08-06 US US17/265,266 patent/US11339153B2/en active Active
- 2019-08-06 EP EP21209598.8A patent/EP3981467A1/en not_active Withdrawn
- 2019-08-06 AU AU2019319750A patent/AU2019319750A1/en active Pending
- 2019-08-06 CN CN201980053552.XA patent/CN112638473B/zh active Active
- 2019-08-06 WO PCT/US2019/045266 patent/WO2020033382A1/en active Application Filing
- 2019-08-06 KR KR1020227015903A patent/KR20220087471A/ko not_active Application Discontinuation
- 2019-08-06 JP JP2021531453A patent/JP7457020B2/ja active Active
- 2019-08-06 CA CA3106033A patent/CA3106033A1/en active Pending
- 2019-08-06 MX MX2021001513A patent/MX2021001513A/es unknown
- 2019-08-06 KR KR1020217005059A patent/KR102398656B1/ko active IP Right Grant
- 2019-08-06 IL IL280520A patent/IL280520B2/en unknown
-
2021
- 2021-01-28 PH PH12021550214A patent/PH12021550214A1/en unknown
- 2021-02-04 SA SA521421189A patent/SA521421189B1/ar unknown
- 2021-02-18 ZA ZA2021/01119A patent/ZA202101119B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019319750A1 (en) | 2021-03-04 |
| EP3833434B1 (en) | 2021-12-15 |
| JP7457020B2 (ja) | 2024-03-27 |
| BR112021002050A2 (pt) | 2021-05-04 |
| JP2021534238A (ja) | 2021-12-09 |
| US11339153B2 (en) | 2022-05-24 |
| MX2021001513A (es) | 2021-06-15 |
| WO2020033382A1 (en) | 2020-02-13 |
| ES2907187T3 (es) | 2022-04-22 |
| KR20210042112A (ko) | 2021-04-16 |
| CA3106033A1 (en) | 2020-02-13 |
| KR102398656B1 (ko) | 2022-05-16 |
| PH12021550214A1 (en) | 2021-10-18 |
| IL280520A (en) | 2021-03-01 |
| US20210309656A1 (en) | 2021-10-07 |
| PL3833434T3 (pl) | 2022-03-07 |
| KR20220087471A (ko) | 2022-06-24 |
| CN112638473A (zh) | 2021-04-09 |
| IL280520B2 (en) | 2023-11-01 |
| EP3833434A1 (en) | 2021-06-16 |
| ZA202101119B (en) | 2022-09-28 |
| EP3981467A1 (en) | 2022-04-13 |
| IL280520B1 (en) | 2023-07-01 |
| SA521421189B1 (ar) | 2023-11-08 |
| CN112638473B (zh) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3833434T3 (da) | Forbindelser, der er nyttige ved modulering af farnesoid-x-receptoren, samt fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3420080T3 (da) | Fremgangsmåde til modulering af dna-repair-resultater | |
| DK3207035T3 (da) | Forbindelser og sammensætninger til modulering af egfr- mutantkinaseaktiviteter | |
| DK3330258T3 (da) | 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme | |
| DK3262008T3 (da) | Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed | |
| DK3510716T3 (da) | Opnåelse og angivelse af komponentkombination, der anvendes til CSI-RS | |
| DK3507408T3 (da) | Fremgangsmåde til fremstilling af nonwoven | |
| DK3362477T3 (da) | Antigenbindingsproteiner, der aktiverer leptinreceptoren | |
| DK3253207T3 (da) | Fremgangsmåde til desinficering af en overflade og sammensætning, der er egnet til anvendelse dertil | |
| DK3436553T3 (da) | Kompatibiliserende og stabiliserende sammensætning til brændselsolier og fremgangsmåde til stabilisering af olierne | |
| DK3215689T3 (da) | Løftemekanisme til at løfte konstruktionsplader, løfteapparatur omfattende denne mekanisme og løftefremgangsmåden under anvendelse af dette apparatur | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3177785T3 (da) | Hjælpemonteringsværktøj til placering af elementer og anvendelse af nævnte værktøj | |
| DK3529262T3 (da) | Fremgangsmåder til fremme af t-cellerespons | |
| DK3856436T3 (da) | Fremgangsmåde til opnåelse af omkostningseffektive, geometrisk komplekse emner | |
| DK3265443T3 (da) | Pyrrolidincarboxamidderivater og fremgangsmåde til fremstilling og anvendelse af samme | |
| DK3161129T3 (da) | Nerveceller, der udtrykker adenovirus e4orf1 og fremgangsmåder til at fremstille og anvende samme | |
| DK3232555T3 (da) | Fremgangsmåde, indretning og system til fordelt styring af undermodul | |
| DK3623321T3 (da) | Transportsystem, fremgangsmåde til fremstilling af transportsystemet | |
| DK3662925T3 (da) | Sammensætning, der omfatter fsh, til behandling af infertilitet | |
| DK3347360T3 (da) | Forbindelser, som er anvendelige til inhibering af ror-gamma-t | |
| DK3313465T3 (da) | Semi-syntestisk pulverformet materiale, opnået ved modifikation af sammensætningen af et naturligt havbiomateriale, fremgangsmåde til fremstilling og anvendelse deraf | |
| DK3538029T3 (da) | Ledimplantat til vævsnydannelse på leddet | |
| DK3403368T3 (da) | 2-faktorgodkendelse til netværksforbundet lagringsindretning | |
| DK3507282T3 (da) | Fremgangsmåde til fremstilling af indolcarboxamidforbindelser |